Rhythm Pharmaceuticals, Inc. ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für Rhythm Pharmaceuticals, Inc. zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um Rhythm Pharmaceuticals, Inc. zu Deinem Portfolio hinzuzufügen.
IMCIVREE expected to be funded and available for use in England and Wales within three months through the National Health Service in specialist centres IMCIVREE expected to be funded and available for use in England and Wales within three months through the National Health Service in specialist centres
Rhythm Pharmaceuticals, Inc (NASDAQ:RYTM ) Q1 2024 Results Conference Call May 7, 2024 8:00 AM ET Company Participants David Connolly - Executive Director, IR and Corporate Communications David Meeker - Chairman, President, and CEO Jennifer Lee - Executive Vice President, Head of North America Yann Mazabraud - Executive Vice President, Head of International Hunter Smith - Chief Financial Office...
While conventional wisdom calls for selling securities, these best Nasdaq stocks may require a complete rethink. With the possibility that the Federal Reserve might get its soft landing after all, risk-on sentiment has returned on Wall Street.
-- First quarter 2024 net revenue from global sales of IMCIVREE ® (setmelanotide) of $26.0 million -- -- On track to submit sNDA to the FDA to treat pediatric patients between 2 and younger than 6 years old in approved indications in second quarter of 2024 --
- Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks and 26% at one year of treatment -
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, May 7, 2024 to report its first quarter 2024 financial resul...
BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on April 11, 2024, the Compensation Committee of Rhythm's board of directors granted inducement equity grants covering an aggregate of 3...
-- Proceeds from financing and existing cash on-hand sufficient to fund planned operations into 2026 -- -- Proceeds from financing and existing cash on-hand sufficient to fund planned operations into 2026 --
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.